| 出品公司: | ZYbscience |
|---|---|
| 载体名称: | pAAV-hSyn-RFP |
| 质粒类型: | 腺病毒载体；荧光报告载体 |
| 高拷贝/低拷贝: | 高拷贝 |
| 克隆方法: | 限制性内切酶，多克隆位点 |
| 启动子: | human Synapsin 1 |
| 载体大小: | 5909 bp |
| 5' 测序引物及序列: | -- |
| 3' 测序引物及序列: | SP6 5'ATTTAGGTGACACTATAG 3' |
| 载体标签: | -- |
| 载体抗性: | 氨苄青霉素 |
| 筛选标记: | 红色荧光蛋白DsRedExpress |
| 克隆菌株: | Stbl3 或 NEB Stble |
| 宿主细胞（系）: | 神经细胞 |
| 备注: | pAAV-hSyn-RFP载体含有human synapsin 1 启动子，适合在神经细胞中表达。 |
| 产品目录号: | ZY22907 |
| 稳定性: | 稳表达 |
| 组成型/诱导型: | 组成型 |
| 病毒/非病毒: | 腺病毒 |
- ¥1100
- ZYbscience
- 中国/美国
- ZY22907
- 2025年07月15日
11 年钻石会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-20℃低温保存
- 保质期：
三年
- 英文名：
pAAV-hSyn-RFP
- 库存：
20
- 供应商：
泽叶生物
载体基本信息
载体质粒图谱和多克隆位点信息
载体简介
载体序列
LOCUS pAAV-hSyn-RFP Sequencing Result 5909 bp DNA SYN
DEFINITION pAAV-hSyn-RFP Sequencing Result
COMMENT This file is created by Vector NTI
http://www.biofeng.com/
COMMENT ORIGDB|GenBank
COMMENT VNTAUTHORNAME|biofeng.com|
COMMENT VNTNAME|pAAV-hSyn-RFP|
SOURCE
ORGANISM other sequences; artificial sequences; vectors.
FEATURES Location/Qualifiers
source 1..5909
/organism="pAAV-hSyn-RFP Sequencing Result"
/mol_type="other DNA"
misc_feature 845..1228
/label="bGlob_int"
CDS 1154..2008
/label="ORF frame 2"
/translation="MFIPLIFLPQLLGNVLVCVLAHHFGKAREFEDLAASASRTSGSP
GLQEFDATGRHHGLLRGRHQGVHALQGAHGGLRERPRVRDRGRGRGPPLRGHPDRQAE
GDQGRPPALRLGHPVPPVPVRLQGVREAPRRHPRLQEAVLPRGLQVGARDELRGRRRG
DRDPGLLPAGRLLHLQGEVHRRELPLRRPRNAEEDYGLGGLHRAPVPPRRRAEGRDPQ
GPEAEGRRPLPGGVQVHLHGQEARAAARLLLRGLQAGHHLPQRGLHHRGAVRARRGPP
PPVPVAAK*"
misc_feature 1265..1281
/label="pBluescriptSK_primer"
/translation="MFIPLIFLPQLLGNVLVCVLAHHFGKAREFEDLAASASRTSGSP
GLQEFDATGRHHGLLRGRHQGVHALQGAHGGLRERPRVRDRGRGRGPPLRGHPDRQAE
GDQGRPPALRLGHPVPPVPVRLQGVREAPRRHPRLQEAVLPRGLQVGARDELRGRRRG
DRDPGLLPAGRLLHLQGEVHRRELPLRRPRNAEEDYGLGGLHRAPVPPRRRAEGRDPQ
GPEAEGRRPLPGGVQVHLHGQEARAAARLLLRGLQAGHHLPQRGLHHRGAVRARRGPP
PPVPVAAK*"
CDS 1302..1997
/label="ORF frame 3"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
gene 1320..1997
/label="DsRed_Express_2"
/gene="DsRed_Express_2"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
gene 1323..1994
/label="DsRed_Express"
/gene="DsRed_Express"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
misc_feature complement(1500..1520)
/label="dsRed1_N_primer"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
misc_feature 1912..1935
/label="dsRed1_C_primer"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
misc_feature complement(2040..2057)
/label="Sp6_primer"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
promoter complement(2041..2058)
/label="Sp6_promoter"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
misc_feature complement(2077..2094)
/label="BGH_rev_primer"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
terminator 2080..2271
/label="bGH_PA_terminator"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
rep_origin 2855..3161
/label="f1_origin"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
misc_feature 3952..3974
/label="pGEX_3_primer"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
promoter 4133..4161
/label="AmpR_promoter"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
gene 4203..5063
/label="Ampicillin"
/gene="Ampicillin"
/translation="MLPVATMASSEDVIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPY
EGTQTAKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERV
MNFEDGGVVTVTQDSSLQDGSFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRD
GVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVE
QYERAEGRHHLFL*"
CDS 4203..5063
/label="ORF frame 3"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
rep_origin 5218..5837
/label="pBR322_origin"
/translation="MSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGY
IELDLNSGKILESFRPEERFPMMSTFKVLLCGAVLSRIDAGQEQLGRRIHYSQNDLVE
YSPVTEKHLTDGMTVRELCSAAITMSDNTAANLLLTTIGGPKELTAFLHNMGDHVTRL
DRWEPELNEAIPNDERDTTMPVAMATTLRKLLTGELLTLASRQQLIDWMEADKVAGPL
LRSALPAGWFIADKSGAGERGSRGIIAALGPDGKPSRIVVIYTTGSQATMDERNRQIA
EIGASLIKHW*"
ORIGIN
1 GTGGATAACC GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC
61 GAGCGCAGCG AGTCAGTGAG CGAGCGAGCG CGCAGAGAGG GAGTGGCCAA CTCCATCACT
121 AGGGGTTCCT TGTAGTTAAT GATTAACCCG CCATGCTACT TATCTACGTA GCCATGCTCT
181 AGAGGATCCT TCGAAAAGCT TCTGCAGAGG GCCCTGCGTA TGAGTGCAAG TGGGTTTTAG
241 GACCAGGATG AGGCGGGGTG GGGGTGCCTA CCTGACGACC GACCCCGACC CACTGGACAA
301 GCACCCAACC CCCATTCCCC AAATTGCGCA TCCCCTATCA GAGAGGGGGA GGGGAAACAG
361 GATGCGGCGA GGCGCGTGCG CACTGCCAGC TTCAGCACCG CGGACAGTGC CTTCGCCCCC
421 GCCTGGCGGC GCGCGCCACC GCCGCCTCAG CACTGAAGGC GCGCTGACGT CACTCGCCGG
481 TCCCCCGCAA ACTCCCCTTC CCGGCCACCT TGGTCGCGTC CGCGCCGCCG CCGGCCCAGC
541 CGGACCGCAC CACGCGAGGC GCGAGATAGG GGGGCACGGG CGCGACCATC TGCGCTGCGG
601 CGCCGGCGAC TCAGCGCTGC CTCAGTCTGC GGTGGGCAGC GGAGGAGTCG TGTCGTGCCT
661 GAGAGCGCAG TCGAGGCGCG CCGAGCTCGG ATCCTGAGAA CTTCAGGGTG AGTCTATGGG
721 ACCCTTGATG TTTTCTTTCC CCTTCTTTTC TATGGTTAAG TTCATGTCAT AGGAAGGGGA
781 GAAGTAACAG GGTACACATA TTGACCAAAT CAGGGTAATT TTGCATTTGT AATTTTAAAA
841 AATGCTTTCT TCTTTTAATA TACTTTTTTG TTTATCTTAT TTCTAATACT TTCCCTAATC
901 TCTTTCTTTC AGGGCAATAA TGATACAATG TATCATGCCT CTTTGCACCA TTCTAAAGAA
961 TAACAGTGAT AATTTCTGGG TTAAGGCAAT AGCAATATTT CTGCATATAA ATATTTCTGC
1021 ATATAAATTG TAACTGATGT AAGAGGTTTC ATATTGCTAA TAGCAGCTAC AATCCAGCTA
1081 CCATTCTGCT TTTATTTTAT GGTTGGGATA AGGCTGGATT ATTCTGAGTC CAAGCTAGGC
1141 CCTTTTGCTA ATCATGTTCA TACCTCTTAT CTTCCTCCCA CAGCTCCTGG GCAACGTGCT
1201 GGTCTGTGTG CTGGCCCATC ACTTTGGCAA AGCACGTGAA TTCGAAGATC TGGCCGCCTC
1261 GGCCTCTAGA ACTAGTGGAT CCCCCGGGCT GCAGGAATTC GATGCTACCG GTCGCCACCA
1321 TGGCCTCCTC CGAGGACGTC ATCAAGGAGT TCATGCGCTT CAAGGTGCGC ATGGAGGGCT
1381 CCGTGAACGG CCACGAGTTC GAGATCGAGG GCGAGGGCGA GGGCCGCCCC TACGAGGGCA
1441 CCCAGACCGC CAAGCTGAAG GTGACCAAGG GCGGCCCCCT GCCCTTCGCC TGGGACATCC
1501 TGTCCCCCCA GTTCCAGTAC GGCTCCAAGG TGTACGTGAA GCACCCCGCC GACATCCCCG
1561 ACTACAAGAA GCTGTCCTTC CCCGAGGGCT TCAAGTGGGA GCGCGTGATG AACTTCGAGG
1621 ACGGCGGCGT GGTGACCGTG ACCCAGGACT CCTCCCTGCA GGACGGCTCC TTCATCTACA
1681 AGGTGAAGTT CATCGGCGTG AACTTCCCCT CCGACGGCCC CGTAATGCAG AAGAAGACTA
1741 TGGGCTGGGA GGCCTCCACC GAGCGCCTGT ACCCCCGCGA CGGCGTGCTG AAGGGCGAGA
1801 TCCACAAGGC CCTGAAGCTG AAGGACGGCG GCCACTACCT GGTGGAGTTC AAGTCCATCT
1861 ACATGGCCAA GAAGCCCGTG CAGCTGCCCG GCTACTACTA CGTGGACTCC AAGCTGGACA
1921 TCACCTCCCA CAACGAGGAC TACACCATCG TGGAGCAGTA CGAGCGCGCC GAGGGCCGCC
1981 ACCACCTGTT CCTGTAGCGG CCAAATGAAT TCCCAAACCG TACGGGAAAC GGCCCTATTC
2041 TATAGTGTCA CCTAAATGCT AGAGCTCGCT GATCAGCCTC GACTGTGCCT TCTAGTTGCC
2101 AGCCATCTGT TGTTTGCCCC TCCCCCGTGC CTTCCTTGAC CCTGGAAGGT GCCACTCCCA
2161 CTGTCCTTTC CTAATAAAAT GAGGAAATTG CATCGCATTG TCTGAGTAGG TGTCATTCTA
2221 TTCTGGGGGG TGGGGTGGGG CAGGACAGCA AGGGGGAGGA TTGGGAAGAC AATAGCGCGG
2281 CCGCTCTAGA GCATGGCTAC GTAGATAAGT AGCATGGCGG GTTAATCATT AACTACAAGG
2341 AACCCCTAGT GATGGAGTTG GCCACTCCCT CTCTGCGCGC TCGCTCGCTC ACTGAGGCCG
2401 GGCGACCAAA GGTCGCCCGA CGCCCGGGCT TTGCCCGGGC GGCCTCAGTG AGCGAGCGAG
2461 CGCGCAGCTG GCGTAATAGC GAAGAGGCCC GCACCGATCG CCCTTCCCAA CAGTTGCGCA
2521 GCCTGAATGG CGAATGGCGA TTCCGTTGCA ATGGCTGGCG GTAATATTGT TCTGGATATT
2581 ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT TACTAATCAA
2641 AGAAGTATTG CGACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT CGGTGGCCTC
2701 ACTGATTATA AAAACACTTC TCAGGATTCT GGCGTACCGT TCCTGTCTAA AATCCCTTTA
2761 ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCTAACGAGG AAAGCACGTT ATACGTGCTC
2821 GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG GTGTGGTGGT
2881 TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT TCGCTTTCTT
2941 CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC GGGGGCTCCC
3001 TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG ATTAGGGTGA
3061 TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA CGTTGGAGTC
3121 CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC CTATCTCGGT
3181 CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGCC TATTGGTTAA AAAATGAGCT
3241 GATTTAACAA AAATTTAACG CGAATTTTAA CAAAATATTA ACGCTTACAA TTTAAATATT
3301 TGCTTATACA ATCTTCCTGT TTTTGGGGCT TTTCTGATTA TCAACCGGGG TACATATGAT
3361 TGACATGCTA GTTTTACGAT TACCGTTCAT CGATTCTCTT GTTTGCTCCA GACTCTCAGG
3421 CAATGACCTG ATAGCCTTTG TAGAGACCTC TCAAAAATAG CTACCCTCTC CGGCATGAAT
3481 TTATCAGCTA GAACGGTTGA ATATCATATT GATGGTGATT TGACTGTCTC CGGCCTTTCT
3541 CACCCGTTTG AATCTTTACC TACACATTAC TCAGGCATTG CATTTAAAAT ATATGAGGGT
3601 TCTAAAAATT TTTATCCTTG CGTTGAAATA AAGGCTTCTC CCGCAAAAGT ATTACAGGGT
3661 CATAATGTTT TTGGTACAAC CGATTTAGCT TTATGCTCTG AGGCTTTATT GCTTAATTTT
3721 GCTAATTCTT TGCCTTGCCT GTATGATTTA TTGGATGTTG GAATCGCCTG ATGCGGTATT
3781 TTCTCCTTAC GCATCTGTGC GGTATTTCAC ACCGCATATG GTGCACTCTC AGTACAATCT
3841 GCTCTGATGC CGCATAGTTA AGCCAGCCCC GACACCCGCC AACACCCGCT GACGCGCCCT
3901 GACGGGCTTG TCTGCTCCCG GCATCCGCTT ACAGACAAGC TGTGACCGTC Tccgggagct
3961 gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc gagACGAAAG GGCCTCGTGA
4021 TACGCCTATT TTTATAGGTT AATGTCATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA
4081 CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA
4141 TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA AAAAGGAAGA
4201 GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC
4261 CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG
4321 CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC
4381 CCGAAGAACG TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT
4441 CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT
4501 TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT
4561 TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC CAACTTACTT CTGACAACGA
4621 TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC
4681 TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA
4741 TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG
4801 CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC
4861 GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT
4921 CTCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT
4981 ACACGACGGG GAGTCAGGCA ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG
5041 CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA CTTTAGATTG
5101 ATTTAAAACT TCATTTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA
5161 TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA
5221 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA
5281 AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA
5341 AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT
5401 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT
5461 TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT
5521 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT
5581 TGGAGCGAAC GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA
5641 CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG
5701 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC
5761 GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA
5821 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA
5881 TGTTCTTTCC TGCGTTATCC CCTGATTCT
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
靶向神经元的血清型⸺AAV-EP+ 神经元作为中枢神经系统的核心功能单元，负责信息处理、传递和存储，是维持认知、运动和感觉功能的基础。随着阿尔茨海默 病、帕金森病、亨廷顿病等神经退行性疾病发病率的不断上升，神经元已成为基因治疗领域的重要靶点。然而，针对大脑神经元 的基因递送面临着独特的挑战：血脑屏障的严密保护、神经元亚型的高度异质性、以及对外源载体的敏感性都限制了传统基因 治疗载体的应用效果。传统 AAV 血清型在跨越血脑屏障和实现神经元特异性转导方面存在效率低、脱靶效应明显等问题。 2025 年 5 月
for itch sensation. [腺相关病毒, 痒, 光遗传,化学遗传]注射部位：小鼠PBN载体：AAV-hSyn-HA-hM4Di-IRES-mCitrine血清型：AAV2/9病毒滴度：1.0× 1013 VG/mL注射体积：150nl观察时间：3周2.基于AAV的逆向非跨突触标记—rAAV2-retro 注射部位：小鼠BPN载体：rAAV2-retro-hSyn-EYFP观察时间：4周3.基于AAV的跨突触标记3.1 基于AAV的顺向跨突触标记-- rAAV2/1 ① 客户发表文章：Nature
除了Ad共转染的需求。辅助质粒表达AAV的rep和cap基因和Ad E2A、VAI和E4基因。当辅助质粒在没有Ad感染的情况下共转染到人293细胞中，rAAV载体产量超过了pAAV/Ad包装质粒的80倍。另外，有复制能力的AAV在rAAV制备过程中少于0.00125%。此系统的主要优点是(1)无需感染性的腺病毒(2)只使用两个质粒就提高了转染效率和载体的产出。我们相信该双质粒转染系统因其简便性和高产出而使AAV载体系统能被更广泛地使用。该系统尤其将对多rAAV载体的临床前分析有用 1．简介 腺相关
技术资料暂无技术资料 索取技术资料
pAAV-hSyn-RFP载体
¥1100
